Small Cell Lung Cancer Pipeline

Small Cell Lung Cancer companies are Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical, Amgen, BeiGene, Genentech, AbbVie, Amgen, Daiichi Sankyo, & others.

ALBANY, NEW YORK, UNITED STATES, March 22, 2024 /EINPresswire.com/ -- As per DelveInsight’s assessment, globally, Small Cell Lung Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Small Cell Lung Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Small Cell Lung Cancer Market.

Some of the key takeaways from the Small Cell Lung Cancer Pipeline Report:
Small Cell Lung Cancer Companies across the globe are diligently working toward developing novel Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.

Small Cell Lung Cancer companies working in the treatment market are Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, Cardiff Oncology, Legend Biotech USA Inc, Bellicum Pharmaceuticals, Genentech, Inc., Phanes Therapeutics, AbbVie, Amgen, Daiichi Sankyo, Inc., HiberCell, Inc., and others, are developing therapies for the Small Cell Lung Cancer treatment

Emerging Small Cell Lung Cancer therapies in the different phases of clinical trials are- RP12146, SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, Onvansertib, LB2102, iC9.GD2.CAR.IL-15 T Infusion, Bevacizumab, PT217, ABBV-011, AMG 404, Ifinatamab Deruxtecan (I-DXd), HC-5404-FU, and others are expected to have a significant impact on the Small Cell Lung Cancer market in the coming years.

In March 2022, Luye Pharma Group has submitted a New Drug Application (NDA) in Hong Kong, China, for Lurbinectedin, targeting the treatment of metastatic Small-cell Lung Cancer (SCLC) in adults experiencing disease progression following prior treatment with platinum-based chemotherapy. Lurbinectedin, an innovative oncology medication, has been licensed to Luye Pharma by PharmaMar.

In March 2022, Harpoon Therapeutics, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to HPN328, a TriTAC^® therapy targeting delta-like ligand 3 (DLL3), intended for treating Small-cell Lung Cancer (SCLC). A Phase 1/2 clinical trial focusing on the SCLC patient group is presently underway for HPN328.

In March 2022, Akeso, Inc. declared a partnership with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to undertake a Phase Ib/II clinical investigation involving a combination treatment. This study aims to explore the effectiveness of Cadonilimab (AK104), a PD-1/CTLA-4 bispecific antibody, and Chiauranib (an Aurora B/VEGFR/PDGFR/c-Kit/CSF1R inhibitor) in patients with Extensive-Stage Small-cell Lung Cancer (ES-SCLC) whose condition progressed after receiving platinum-based chemotherapy and PD-(L)1 inhibitor as initial therapy.

In March 2022, Shanghai Henlius Biotech, Inc., has announced the approval of the investigational new drug application (IND) by the National Medical Products Administration (NMPA) for international multicenter phase 3 studies of HANSIZHUANG (serplulimab). This innovative anti-PD-1 monoclonal antibody (mAb), independently developed by the Company, will be evaluated in combination with chemotherapy and concurrent radiotherapy in patients diagnosed with limited-stage Small-Cell Lung Cancer (LS-SCLC). Earlier, the global multi-center phase 3 study of HANSIZHUANG focusing on first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) successfully met the primary study endpoint of overall survival (OS). Anticipated filings for New Drug Application (NDA) in China and Marketing Authorization Application (MAA) in the EU are expected in 2022, potentially positioning HANSIZHUANG as the world’s inaugural PD-1 inhibitor for the first-line treatment of SCLC.

In January 2022, Genprex, Inc. made public its extension of the oncology research and development pipeline to encompass Small-cell Lung Cancer (SCLC) as an added disease indication for its primary drug candidate, REQORSA™ Immunogene Therapy.

In July 2021, Sorrento Therapeutics has commenced a Phase III clinical trial, which is randomized, double-blind, and placebo-controlled, investigating Carboplatin Plus Etoposide in combination with or without ZKAB001 (an Anti-PD-L1 Antibody) among patients diagnosed with untreated extensive-stage Small Cell Lung Cancer.

Small Cell Lung Cancer Overview
Because the cancer cells exhibit characteristics of both neuron and endocrine (hormone-secreting) cells, small cell lung cancer is classified as a neuroendocrine carcinoma. Hormone-secreting cells are found in specialized tissue called endocrine tissue. These hormones perform a number of different tasks in the body.

Get a Free Sample PDF Report to know more about Small Cell Lung Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Emerging Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
RP12146: Rhizen Pharmaceuticals
SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
AK104: Akeso
APG 1252: Ascentage Pharma
BNT 411: BioNTech
QL1706: Qilu Pharmaceutical Co
Tarlatamab: Amgen
Tislelizumab: BeiGene
Socazolimab: Sorrento Therapeutics
Onvansertib: Cardiff Oncology
LB2102: Legend Biotech USA Inc
iC9.GD2.CAR.IL-15 T Infusion: Bellicum Pharmaceuticals
Bevacizumab: Genentech, Inc.
PT217: Phanes Therapeutics
ABBV-011: AbbVie
AMG 404: Amgen
Ifinatamab Deruxtecan (I-DXd): Daiichi Sankyo, Inc.
HC-5404-FU: HiberCell, Inc.

Small Cell Lung Cancer Route of Administration
Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical
Molecule Type

Download Sample PDF Report to know more about Small Cell Lung Cancer drugs and therapies

Small Cell Lung Cancer Molecule Type
Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Small Cell Lung Cancer Pipeline Therapeutics Assessment
Small Cell Lung Cancer Assessment by Product Type
Small Cell Lung Cancer By Stage and Product Type
Small Cell Lung Cancer Assessment by Route of Administration
Small Cell Lung Cancer By Stage and Route of Administration
Small Cell Lung Cancer Assessment by Molecule Type
Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s Small Cell Lung Cancer Report covers around 100+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Some of the key companies in the Small Cell Lung Cancer Therapeutics Market include:
Key companies developing therapies for Small Cell Lung Cancer are – Medicine Invention Design, Inc, Advenchen Laboratories, LLC, Bristol-Myers Squibb, Clovis Oncology, Inc., Cardiff Oncology, Legend Biotech USA Inc, Bellicum Pharmaceuticals, Genentech, Inc., Phanes Therapeutics, AbbVie, Amgen, Daiichi Sankyo, Inc., HiberCell, Inc., Hoffmann-La Roche, Harpoon Therapeutics, BioNTech SE, Boehringer Ingelheim, Chipscreen Biosciences, Ltd., Andarix Pharmaceuticals, Telix International Pty Ltd, Syros Pharmaceuticals, Jacobio Pharmaceuticals Co., Ltd., Cybrexa Therapeutics, and others.

Request for Sample PDF Report for Small Cell Lung Cancer Pipeline Assessment and clinical trials

Small Cell Lung Cancer Pipeline Analysis:
The Small Cell Lung Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment.
Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Small Cell Lung Cancer Pipeline Market Drivers
Rising incidence of Small Cell Lung Cancer, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Small Cell Lung Cancer Market.

Small Cell Lung Cancer Pipeline Market Barriers
However, the management of SCLC is problematic due to the aggressive nature of this type of cancer, rise in cost of treatment, poor prognosis of the disease in comparison with non-small cell lung cancer and other factors are creating obstacles in the Small Cell Lung Cancer Market growth.

Scope of Small Cell Lung Cancer Pipeline Drug Insight
Coverage: Global
Key Small Cell Lung Cancer Companies: Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, Cardiff Oncology, Legend Biotech USA Inc, Bellicum Pharmaceuticals, Genentech, Inc., Phanes Therapeutics, AbbVie, Amgen, Daiichi Sankyo, Inc., HiberCell, Inc., and others
Key Small Cell Lung Cancer Therapies: RP12146, SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, Onvansertib, LB2102, iC9.GD2.CAR.IL-15 T Infusion, Bevacizumab, PT217, ABBV-011, AMG 404, Ifinatamab Deruxtecan (I-DXd), HC-5404-FU, and others
Small Cell Lung Cancer Therapeutic Assessment: Small Cell Lung Cancer current marketed and Small Cell Lung Cancer emerging therapies
Small Cell Lung Cancer Market Dynamics: Small Cell Lung Cancer market drivers and Small Cell Lung Cancer market barriers

Table of Contents
1. Small Cell Lung Cancer Report Introduction
2. Small Cell Lung Cancer Executive Summary
3. Small Cell Lung Cancer Overview
4. Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
5. Small Cell Lung Cancer Pipeline Therapeutics
6. Small Cell Lung Cancer Late Stage Products (Phase II/III)
7. Small Cell Lung Cancer Mid Stage Products (Phase II)
8. Small Cell Lung Cancer Early Stage Products (Phase I)
9. Small Cell Lung Cancer Preclinical Stage Products
10. Small Cell Lung Cancer Therapeutics Assessment
11. Small Cell Lung Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Small Cell Lung Cancer Key Companies
14. Small Cell Lung Cancer Key Products
15. Small Cell Lung Cancer Unmet Needs
16. Small Cell Lung Cancer Market Drivers and Barriers
17. Small Cell Lung Cancer Future Perspectives and Conclusion
18. Small Cell Lung Cancer Analyst Views
19. Appendix
20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Ankit Nigam
DelveInsight Business Research
+1 469-945-7679
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.